2상모집 중

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

연구 개요

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

스폰서: 협력: 아스트라제네카, BMS, 화이자, 로슈
적응증: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
중재: Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
목표 등록: 720명
시작일: 2018-03-23
완료(예정): 2027-01-31
등록번호: NCT03297606 · ClinicalTrials.gov ↗

상태 변경 이력

2026-07-18조기 종료→모집 중

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.